


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1. – 29. (Cancelled).

30. (Currently amended) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a total daily dose of up to 600 mg of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:



or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA or a pharmaceutically acceptable salt or hydrate thereof is effective to treat diffuse large B-cell lymphoma in said subject.

31. (Cancelled).

32. (Previously presented) The method of claim 30, wherein said composition is contained within a gelatin capsule.

33. (Original) The method of claim 32, wherein said carrier or diluent is microcrystalline cellulose.

34. (Original) The method of claim 33, further comprising sodium croscarmellose as a disintegrating agent.

35. (Original) The method of claim 34, further comprising magnesium stearate as a lubricant.

36. (Cancelled).

37. (Previously presented) The method of claim 30, wherein said composition is administered once-daily, twice-daily or three times-daily.

38. (Previously presented) The method of claim 37, wherein said composition is administered once daily at a dose of 200-600 mg.

39. (Previously presented) The method of claim 37, wherein said composition is administered twice daily at a dose of 150 mg, 200 mg, or 300 mg.

40. (Previously presented) The method of claim 37, wherein said composition is administered twice daily at a dose of 150 mg, 200 mg, or 300 mg intermittently.

41. (Original) The method of claim 40, wherein said composition is administered three to five days per week.

42. (Original) The method of claim 40, wherein said composition is administered three days a week.

43. (Previously presented) The method of claim 42, wherein said composition is administered at a dose of 200 mg.


44. (Previously presented) The method of claim 42, wherein said composition is administered at a dose of 300 mg.

45. (Previously presented) The method of claim 42, wherein said composition is administered at a dose of 400 mg.

46. (Previously presented) The method of claim 37, wherein said composition is administered three times daily at a dose of 100 mg or 150 mg.

47. (Currently amended) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a total daily dose of up to 800 mg of a pharmaceutical composition comprising suberoylanilide hydroxamic acid

(SAHA) represented by the structure:



or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier or diluent, wherein administration of SAHA or a pharmaceutically acceptable salt or hydrate thereof is effective to treat diffuse large B-cell lymphoma in said subject.

48. (Cancelled).

49. (Previously presented) The method of claim 47, wherein said composition is contained within a gelatin capsule.

50. (Original) The method of claim 49, wherein said carrier or diluent is microcrystalline cellulose.

51. (Original) The method of claim 50, further comprising sodium croscarmellose as a disintegrating agent.

52. (Original) The method of claim 51, further comprising magnesium stearate as a lubricant.

53. (Previously presented) The method of claim 47, wherein said composition is administered once-daily, twice-daily or three times-daily.

54. (Previously presented) The method of claim 53, wherein said composition is administered once daily at a dose of 200-600 mg.

55. (Previously presented) The method of claim 53, wherein said composition is administered twice daily at a dose of 200-400 mg.

56. (Previously presented) The method of claim 53, wherein said composition is administered twice daily at a dose of 200-400 mg intermittently.

57. (Original) The method of claim 56, wherein said composition is administered three to five days per week.

58. (Original) The method of claim 56, wherein said composition is administered three days a week.

59. (Previously presented) The method of claim 58, wherein said composition is administered at a dose of 200 mg.

60. (Previously presented) The method of claim 58, wherein said composition is administered at a dose of 300 mg.

61. (Previously presented) The method of claim 58, wherein said composition is administered at a dose of 400 mg.

62. (Previously presented) The method of claim 53, wherein said composition is administered three times daily at a dose of 100-250 mg.

63. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg continuously.

64. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg continuously.

65. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg intermittently.


66. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg intermittently.

67. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 400 mg for 14 consecutive days in a 21 day schedule.

68. (Previously presented) The method of claim 38, wherein said composition is administered at a dose of 600 mg for 14 consecutive days in a 21 day schedule.


69. (Previously presented) The method of any one of claims 30, 32-35, 37-47, or 49-68, wherein SAHA is administered.

70. (Currently amended) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of continuously administering to the subject an oral daily dose of 400 mg once per day of a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:



~~as the active ingredient and a pharmaceutically acceptable carrier or diluent~~, wherein administration of SAHA is effective to treat diffuse large B-cell lymphoma in said subject.

71. (Currently amended) A method of treating diffuse large B-cell lymphoma in a subject, said method comprising the step of ~~continuously~~ administering to the subject ~~a~~ pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) represented by the structure:



~~as the active ingredient and a pharmaceutically acceptable carrier or diluent~~, wherein said composition is administered twice daily at a dose of 300 mg three days a week, and wherein said administration of SAHA is effective to treat diffuse large B-cell lymphoma in said subject.